ADTRAN
11.3.2024 14:02:25 CET | Business Wire | Press release
Adtran today announced that Netnod is leveraging its optical pumping cesium atomic clock technology to bring precise, reliable and assured timing to Sweden’s critical national infrastructure. Protecting the country’s timing services is vital for the nation’s economy, encompassing finance, digital services and next-generation telecoms networks, such as 5G. By upgrading its timing network with the coreSync™ OSA 3300-HP, Netnod, the leading provider of internet exchange, DNS and time services in the Nordics, is enhancing the accuracy, stability and longevity of synchronization services across the region. The solution meets the need for precise timing, supporting the smooth operation and evolution of digital applications and services. It represents a significant advancement in timing that enhances Sweden’s position in digital innovation and cybersecurity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311684053/en/
Netnod is using Adtran’s synchronization technology for ultra-precise and reliable timing across Sweden’s national critical infrastructure. (Photo: Business Wire)
“At Netnod, we’re committed to providing the market’s most advanced and reliable timing solutions. Our new Time Direct and Remote services, built on the latest timing standards and security protocols, underscore our leadership in this domain. The deployment of Adtran’s coreSync™ OSA 3300-HP is key for providing reliable, continuous timing for Sweden’s critical infrastructure. It enhances our NTP/PTP services and strengthens Sweden’s digital backbone for essential sectors, including 5G. It also provides the country with the benefits of highly precise synchronization resilient against GNSS vulnerabilities and enables us to deliver more valuable SLAs for our customers,” said Karin Ahl, CEO of Netnod. “This upgrade is about securing the digital backbone of our nation against GNSS cyber threats, generating economic growth and reinforcing our commitment to maintaining Sweden as a leader in digital innovation and infrastructure resilience.”
Netnod is integrating Oscilloquartz super ePRC technology across six key timing centers nationwide, including the coreSync™ OSA 3300-HP, for unprecedented reliability and accuracy. The upgrade is particularly crucial for timing service assurance within a secure environment. Given the increasing vulnerabilities of GNSS, the optically pumped cesium technology offers a highly stable and accurate alternative timing source. The coreSync™ OSA 3300-HP sets new standards with its higher frequency stability and lifespan that is twice as long as traditional magnetic clocks. Its robust design is complemented by a user-friendly LCD touchscreen and Ethernet connectivity, facilitating both local and remote configuration and management. This blend of advanced features enhances time synchronization across Sweden and prepares the nation’s infrastructure for future challenges.
“Netnod is a major hub for ICT and multimedia, serving as the gateway to the Nordics’ global digital arena. Leveraging our coreSync™ OSA 3300, it’s fortifying Sweden’s critical national infrastructure, ensuring seamless operations and growth for internet service providers, content delivery networks and businesses in one of Europe’s most dynamic digital markets,” commented Stuart Broome, GM of EMEA sales at Adtran. “With our technology, Netnod can utilize multiple timing sources, enabling a zero-trust environment for clients in next-gen telecoms, finance, utilities, broadcast and beyond. This will help equip enterprises and institutions across the region with top-tier internet speed, resilience and connectivity and solidify Netnod’s position as the digital cornerstone of the Nordics.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About Netnod
Netnod provides critical infrastructure support ranging from interconnection services and Internet Exchanges to time services, DNS services and root server operations. With a worldwide reputation for its services and the expertise of its staff, Netnod ensures a stable and secure Internet for the Nordics and beyond. Established in 1996 as a neutral and independent Internet infrastructure organisation, Netnod is fully owned by the non-profit foundation TU-stiftelsen (Stiftelsen för Telematikens utveckling). More information is available at: www.netnod.se.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311684053/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
